| Biomarker ID | 697 |
| PMID | 21788966 |
| Year | 2011 |
| Biomarker | EZH2 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in Intermediate and further upregulated in High Risk Group |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Cell differentiation pathway,MicroRNAs in muscle cell differentiation, PRC2 complex long-term gene silencing through modification of histone tails,Interleukin-2 signaling pathway |
| Experiment | Low Vs Intermediate Vs High Risk Group |
| Type of Biomarker | Prognostic |
| Cohort | Total of 176 people were included in the study. For the full PSA range: 91 patients with PCa and 85 with non-PCa selected. Risk groups in the range of serum PSA = 3–15 ng /ml were chosen for the study. Risk Groups included Low (n=10), Intermediate (n=36) and High (n=45) were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044) |
| Method Used | qPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | EZH2 |